Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 9/20 | 0.78 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.61 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.61 |
| ▸ | KDM1A | O60341 | 7/20 | 0.60 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.52 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.52 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.52 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12191071 | 0.89 | HDAC1 (0.77) | HDAC1SCN2ASCN10AKDM1AAKR1C3 | |
| SCHEMBL12190918 | 0.86 | HDAC1 (0.69) | HDAC1SCN2ASCN10AKDM1AAKR1C3 | |
| SCHEMBL12190882 | 0.83 | SCN2A (0.62) | HDAC1SCN2ASCN10AKDM1AMAOB | |
| SCHEMBL12190886 | 0.82 | HDAC1 (0.66) | HDAC1SCN2ASCN10AKDM1AMAOB | |
| SCHEMBL12191062 | 0.82 | HDAC1 (0.67) | HDAC1SCN2ASCN10AKDM1A | |
| SCHEMBL12190895 | 0.80 | SCN2A (0.61) | HDAC1SCN2ASCN10AKDM1AMAOB | |
| SCHEMBL13947068 | 0.79 | ALDH1A1 (0.69) | HDAC1 | |
| SCHEMBL4491907 | 0.79 | ALDH1A1 (0.69) | HDAC1 | |
| SCHEMBL12191112 | 0.79 | HDAC1 (0.63) | HDAC1SCN2ASCN10AKDM1A | |
| SCHEMBL12191000 | 0.79 | HDAC1 (0.62) | HDAC1SCN2ASCN10AKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030336-B2 | Nicotinamide-based kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2011-10-04 | — | — | US | disclosed |
| US-8030336-B2 | Nicotinamide-based kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2011-10-04 | — | — | US | disclosed |
| US-20070060619-A1 | Nicotinamide-based kinase inhibitors | CYTOPIA PTY LTD (AU) | 2007-03-15 | — | — | US | disclosed |
| US-20070060619-A1 | Nicotinamide-based kinase inhibitors | CYTOPIA PTY LTD (AU) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060619-A1 | Nicotinamide-based kinase inhibitors | NADK, NAMPT, PDXK | HDAC1 147/4885SCN2A 1134/4885SCN10A 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.